Charles Swanton

Summary

Affiliation: Cancer Research UK
Country: UK

Publications

  1. pmc Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target
    Marco Gerlinger
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, Lincoln s Inn Fields, London, WC2A 3LY, UK
    J Pathol 227:146-56. 2012
  2. pmc Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status
    Qiyuan Li
    Center for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark
    PLoS ONE 5:e15031. 2010
  3. pmc How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
    M Gerlinger
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3LY, UK
    Br J Cancer 103:1139-43. 2010
  4. pmc A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit
    A T Brunetto
    The Royal Marsden Hospital Drug Development and Breast Units and Institute of Cancer Research, Sutton, UK
    Br J Cancer 103:607-12. 2010
  5. pmc Cancer heterogeneity: implications for targeted therapeutics
    R Fisher
    University College London Cancer Institute, London, UK
    Br J Cancer 108:479-85. 2013
  6. pmc Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer
    Dean A Fennell
    University of Leicester and Leicester University Hospitals, Hodgkin Building, Lancaster Road, PO Box 138, Leicester, LE1 9HN, UK
    EPMA J 3:6. 2012
  7. pmc Intratumor heterogeneity: evolution through space and time
    Charles Swanton
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, United Kingdom
    Cancer Res 72:4875-82. 2012
  8. pmc Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer
    Hilda Wong
    Division of Hematology and Medical Oncology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
    Oncologist 16:1535-46. 2011
  9. pmc Breast cancer genome heterogeneity: a challenge to personalised medicine?
    Charles Swanton
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
    Breast Cancer Res 13:104. 2011
  10. doi From genomic landscapes to personalized cancer management-is there a roadmap?
    Charles Swanton
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, United Kingdom
    Ann N Y Acad Sci 1210:34-44. 2010

Detail Information

Publications62

  1. pmc Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target
    Marco Gerlinger
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, Lincoln s Inn Fields, London, WC2A 3LY, UK
    J Pathol 227:146-56. 2012
    ..These data suggest that MCT4 may serve as a novel metabolic target to reverse the Warburg effect and limit disease progression in ccRCC...
  2. pmc Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status
    Qiyuan Li
    Center for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark
    PLoS ONE 5:e15031. 2010
    ....
  3. pmc How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
    M Gerlinger
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3LY, UK
    Br J Cancer 103:1139-43. 2010
    ....
  4. pmc A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit
    A T Brunetto
    The Royal Marsden Hospital Drug Development and Breast Units and Institute of Cancer Research, Sutton, UK
    Br J Cancer 103:607-12. 2010
    ..This retrospective series reviews the outcome of 70 MBC patients who have participated in 30 phase I trials at the Royal Marsden Hospital from 2002 to 2009...
  5. pmc Cancer heterogeneity: implications for targeted therapeutics
    R Fisher
    University College London Cancer Institute, London, UK
    Br J Cancer 108:479-85. 2013
    ..The current evidence for intra-tumour heterogeneity and its relevance to cancer therapeutics will be presented in this mini-review...
  6. pmc Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer
    Dean A Fennell
    University of Leicester and Leicester University Hospitals, Hodgkin Building, Lancaster Road, PO Box 138, Leicester, LE1 9HN, UK
    EPMA J 3:6. 2012
    ....
  7. pmc Intratumor heterogeneity: evolution through space and time
    Charles Swanton
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, United Kingdom
    Cancer Res 72:4875-82. 2012
    ....
  8. pmc Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer
    Hilda Wong
    Division of Hematology and Medical Oncology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
    Oncologist 16:1535-46. 2011
    ..The identification of predictive biomarkers is of paramount importance to optimize health economic costs and enhance stratification of anti-HER-2 targeted therapies...
  9. pmc Breast cancer genome heterogeneity: a challenge to personalised medicine?
    Charles Swanton
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
    Breast Cancer Res 13:104. 2011
    ....
  10. doi From genomic landscapes to personalized cancer management-is there a roadmap?
    Charles Swanton
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, United Kingdom
    Ann N Y Acad Sci 1210:34-44. 2010
    ..We argue that the failure to adopt these methods rapidly into clinical trial design will increase late stage drug attrition, waste trial resources, and risk patient harm within unselected cohorts...
  11. ncbi Initiation of high frequency multi-drug resistance following kinase targeting by siRNAs
    Charles Swanton
    Signal Transduction Laboratory, Cancer Research UK London Research Institute, London, UK
    Cell Cycle 6:2001-4. 2007
    ..Furthermore, this work supports efforts to identify common pathways of drug response for future drug discovery programmes...
  12. pmc Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets
    Charles Swanton
    Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London, WC2A 3PX, UK
    Genome Med 2:53. 2010
    ....
  13. ncbi Chromosomal instability, colorectal cancer and taxane resistance
    Charles Swanton
    Royal Marsden Hospital, Department of Medicine, London, UK
    Cell Cycle 5:818-23. 2006
    ..A phase II trial of taxanes in patients with metastatic CIN negative CRC may be indicated...
  14. pmc Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer
    Charles Swanton
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, UK
    Breast Cancer Res 10:214. 2008
    ....
  15. doi Parallel evolution of tumour subclones mimics diversity between tumours
    Pierre Martinez
    Cancer Research UK London Research Institute, London, UK
    J Pathol 230:356-64. 2013
    ....
  16. doi CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction
    Alvin J X Lee
    Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3LY, UK
    J Pathol 226:482-94. 2012
    ....
  17. doi Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials
    Nicolai Juul
    Center for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark
    Lancet Oncol 11:358-65. 2010
    ..Here, we assess these genes as a predictor of pCR to paclitaxel combination chemotherapy in triple-negative breast cancer...
  18. doi Cancer heterogeneity and "the struggle for existence": diagnostic and analytical challenges
    Stuart Horswell
    Cancer Research UK London Research Institute, London, UK Electronic address
    Cancer Lett 340:220-6. 2013
    ....
  19. ncbi Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
    Marco Gerlinger
    1 Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, UK 2
    Nat Genet 46:225-33. 2014
    ..The proportion of C>T transitions at CpG sites increased during tumor progression. M-seq permits the temporal resolution of ccRCC evolution and refines mutational signatures occurring during tumor development. ..
  20. pmc Paradoxical relationship between chromosomal instability and survival outcome in cancer
    Nicolai J Birkbak
    Center for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark
    Cancer Res 71:3447-52. 2011
    ..Inclusion of a surrogate measurement of CIN may improve cancer risk stratification and future therapeutic approaches...
  21. ncbi Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs
    Charles Swanton
    Signal Transduction, Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
    Cancer Cell 11:498-512. 2007
    ..COL4A3BP expression is increased in drug-resistant cell lines and in residual tumor following paclitaxel treatment of ovarian cancer, suggesting that it could be a target for chemotherapy-resistant cancers...
  22. doi Intratumor heterogeneity and branched evolution revealed by multiregion sequencing
    Marco Gerlinger
    Cancer Research UK London Research Institute, London, United Kingdom
    N Engl J Med 366:883-92. 2012
    ..Intratumor heterogeneity may foster tumor evolution and adaptation and hinder personalized-medicine strategies that depend on results from single tumor-biopsy samples...
  23. pmc Chromosomal instability determines taxane response
    Charles Swanton
    Cancer Research UK, London Research Institute, London WC2A 3PX, United Kingdom
    Proc Natl Acad Sci U S A 106:8671-6. 2009
    ..Thus, pretherapeutic assessment of CIN may optimize treatment stratification and clinical trial design using these agents...
  24. doi Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer
    REBECCA A BURRELL
    Translational Cancer Therapeutics Laboratory, London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
    J Cell Biochem 111:782-90. 2010
    ..A greater understanding of karyotypic complexity and identification of methods to directly examine and target CIN may support novel strategies to improve outcome in cancer...
  25. ncbi Replication stress links structural and numerical cancer chromosomal instability
    REBECCA A BURRELL
    Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3LY, UK
    Nature 494:492-6. 2013
    ..These data implicate a central role for replication stress in the generation of structural and numerical CIN, which may inform new therapeutic approaches to limit intratumour heterogeneity...
  26. pmc Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer
    Rebecca Roylance
    Cancer Research UK, London Research Institute, London, United Kingdom
    Cancer Epidemiol Biomarkers Prev 20:2183-94. 2011
    ....
  27. pmc Chromosomal instability confers intrinsic multidrug resistance
    Alvin J X Lee
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, United Kingdom
    Cancer Res 71:1858-70. 2011
    ..Our results suggest that stratifying tumor responses according to CIN status should be considered within the context of clinical trials to minimize the confounding effects of tumor CIN status on drug sensitivity...
  28. doi Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas
    Marco Gerlinger
    Cancer Research UK, London Research Institute, UK Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, London, UK
    J Pathol 231:424-32. 2013
    ..These were polyclonal and displayed ITH in ccRCC. TCRb sequencing may shed light on mechanisms of cancer immunity and the efficacy of immunotherapy approaches...
  29. ncbi Chromosomal instability: a composite phenotype that influences sensitivity to chemotherapy
    Sarah E McClelland
    Translational Cancer Therapeutics Laboratory, Cancer Research UK, London Research Institute, London, UK
    Cell Cycle 8:3262-6. 2009
    ....
  30. doi Implications of intratumour heterogeneity for treatment stratification
    Andrew Crockford
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, London, WC2A 3LY, UK
    J Pathol 232:264-73. 2014
    ..We also discuss the predictive potential of patient-derived models of tumour response, including xenograft and cell line-based systems within the context of intratumour heterogeneity...
  31. pmc A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables
    David Endesfelder
    Cancer Research UK London Research Institute, London, WC2A 3LY, United Kingdom
    Oncotarget 2:529-37. 2011
    ..These data support the hypothesis that chromosomal instability may be a defining feature of breast cancer biology and clinical outcome...
  32. doi Unraveling the complexity of endocrine resistance in breast cancer by functional genomics
    Charles Swanton
    Cancer Research UK London Research Institute, Signal Transduction Laboratory, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
    Cancer Cell 13:83-5. 2008
    ..CDK10 is thus a potential biomarker for sensitivity in prospective clinical trials of patients treated with endocrine therapies...
  33. doi Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution
    Sally M Dewhurst
    1Cancer Research UK London Research Institute 2Centre for Mathematics and Physics in the Life Sciences and Experimental Biology CoMPLEX, University College London 3UCL Cancer Institute, London, United Kingdom 4Department of Mathematics and Technology, University of Applied Sciences Koblenz, Remagen, Germany 5Technical University of Denmark DTU, Lyngby, Denmark 6Systems Biology and Personalised Medicine Division, Walter and Eliza Hall Institute 7Faculty of Medicine, Dentistry and Health Sciences, Department of Surgery and 8Department of Medical Oncology, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria 9Lowy Cancer Research Centre, Prince of Wales Clinical School 10School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia and 11Harvard Medical School, Boston, Massachusetts
    Cancer Discov 4:175-85. 2014
    ..Furthermore, we demonstrate that a genome-doubling event is prognostic of poor relapse-free survival in this disease type...
  34. pmc Cancer chromosomal instability: therapeutic and diagnostic challenges
    Nicholas McGranahan
    Translational Cancer Therapeutics Laboratory, CRUK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
    EMBO Rep 13:528-38. 2012
    ..The relationship between CIN and prognosis supports assessment of CIN status in the clinical setting and suggests that stratifying tumours according to levels of CIN could facilitate clinical risk assessment...
  35. doi Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics
    Alvin J X Lee
    Translational Cancer Therapeutics, Cancer Research UK London Research Institute, UK
    Biochem Pharmacol 83:1013-20. 2012
    ....
  36. ncbi Genetic prognostic and predictive markers in colorectal cancer
    Axel Walther
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, SM2 5PT, UK
    Nat Rev Cancer 9:489-99. 2009
    ..In this Review, we attempt to summarize the sometimes confusing findings, and critically assess those markers already in the public domain...
  37. doi Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference
    Daniel S W Tan
    Translational Cancer Therapeutics Laboratory, Cancer Research UK, London Research Institute, London, United Kingdom
    Eur J Cancer 46:2166-77. 2010
    ..This represents a rational approach to accelerate biomarker discovery, maximising the potential for therapeutic benefit and minimising the health economic cost of ineffective therapy...
  38. doi The causes and consequences of genetic heterogeneity in cancer evolution
    REBECCA A BURRELL
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3LY, UK
    Nature 501:338-45. 2013
    ..By understanding these mechanisms we can gain insight into the common pathways of tumour evolution that could support the development of future therapeutic strategies. ..
  39. doi Intratumor heterogeneity: seeing the wood for the trees
    Timothy A Yap
    Department of Medicine, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    Sci Transl Med 4:127ps10. 2012
    ..Envisaging tumor growth as a Darwinian tree with the trunk representing ubiquitous mutations and the branches representing heterogeneous mutations may help in drug discovery and the development of predictive biomarkers of drug response...
  40. ncbi RNA interference, DNA methylation, and gene silencing: a bright future for cancer therapy?
    Charles Swanton
    Signal Transduction Laboratory, Cancer Research UK London Research Institute, London, UK
    Lancet Oncol 5:653-4. 2004
  41. doi Epigenetic regulation in RCC: opportunities for therapeutic intervention?
    James Larkin
    Department of Medicine, The Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Nat Rev Urol 9:147-55. 2012
    ..An improved understanding of histone and chromatin regulation in RCC biology and the consequences of intratumor heterogeneity might identify novel targets in RCC and present alternative therapeutic opportunities...
  42. doi Computational optimisation of targeted DNA sequencing for cancer detection
    Pierre Martinez
    Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3LY, UK
    Sci Rep 3:3309. 2013
    ..Our analyses demonstrate that targeting "hotspot" regions would introduce biases towards in-frame mutations and would compromise the reproducibility of tumour detection. ..
  43. pmc LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development
    Liwen Lu
    Lungs for Living Research Centre, UCL Respiratory, University College London, 5 University Street, London, WC1E 6JF, UK
    J Pathol 229:608-20. 2013
    ..Our findings imply that the early stages of squamous carcinoma development are driven by a change in amplitude of EGFR signalling governed by the loss of contact inhibition...
  44. pmc Predictive performance of microarray gene signatures: impact of tumor heterogeneity and multiple mechanisms of drug resistance
    Charlotte K Y Ng
    Authors Affiliations Departments of Pathology and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York Cancer Research UK Clinical Trials Unit, The Institute of Cancer Research, Sutton Cancer Research UK London Research Institute and University College London Cancer Institute, London, United Kingdom
    Cancer Res 74:2946-61. 2014
    ..Our work supports the hypothesis that the presence of multiple resistance mechanisms in a given therapy in patients limits the ability of gene signatures to make clinically useful predictions...
  45. doi Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action
    James Larkin
    Renal Cancer Unit, Department of Medicine, Royal Marsden Hospital, London SW3 6JJ, UK
    Expert Rev Anticancer Ther 11:639-49. 2011
    ..Ongoing research will further define the relative merits of other sequences in terms of clinical outcome...
  46. doi Response to bakhoum et Al
    REBECCA A BURRELL
    Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3LY, UK
    Curr Biol 24:R150. 2014
    ..We therefore favour the broader definition of CIN as "losses and gains of whole chromosomes or large portions thereof" as described by the Vogelstein laboratory [6] and commonly used by others. ..
  47. doi Adapting clinical paradigms to the challenges of cancer clonal evolution
    Nirupa Murugaesu
    University College London Cancer Institute, London, United Kingdom
    Am J Pathol 182:1962-71. 2013
    ....
  48. doi Recent developments in treatment stratification for metastatic breast cancer
    Sarah Barton
    Breast Unit, Royal Marsden Hospital, London and Sutton, UK
    Drugs 71:2099-113. 2011
    ..The future management of MBC will increasingly focus on stratifying therapeutics based on individualized-tumour molecular aberrations...
  49. ncbi Her2-targeted therapies in non-small cell lung cancer
    Charles Swanton
    Cancer Research UK London Research Institute, Signal Transduction Laboratory, UK
    Clin Cancer Res 12:4377s-4383s. 2006
    ..The most promising Her2-targeted strategy will likely prove to be combinatorial approaches using an EGFR tyrosine kinase inhibitor together with Her2 dimerization inhibitors...
  50. doi RNAi-mediated functional analysis of pathways influencing cancer cell drug resistance
    Alvin J X Lee
    Translational Cancer Therapeutics Laboratory, Cancer Research UK, London Research Institute, London, UK
    Expert Rev Mol Med 11:e15. 2009
    ..The challenge is how to integrate these data with biological samples to define relevant drug-resistant pathways in vivo...
  51. pmc Tumour heterogeneity and immune-modulation
    Mariam Jamal-Hanjani
    Translational Cancer Therapeutics Laboratory, Cancer Research UK, London Research Institute, London WC2A 3LY, UK
    Curr Opin Pharmacol 13:497-503. 2013
    ....
  52. ncbi Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab
    Thomas Yau
    Breast Unit, Royal Marsden Hospital, Surrey SM2 5PT, UK
    Acta Oncol 45:196-201. 2006
    ..This study shows brain metastases are common phenomenon in HER2 positive advanced breast cancer patients receiving trastuzumab and also may implicate the brain as a sanctuary site for early relapse in this patient cohort...
  53. ncbi New Targets and Innovative Strategies in Cancer Treatment: one year of progress. 13-14 February 2004, Nice, France
    Charles Swanton
    Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    IDrugs 7:306-11. 2004
  54. ncbi Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies
    Sarah Barton
    Royal Marsden Hospital, Department of Medicine, Breast Unit, Downs Road, Sutton, SM2 5PT, UK
    Curr Cancer Drug Targets 10:799-812. 2010
    ..Functional genomics elucidation of drug resistance pathways using RNA interference (RNAi) techniques may provide novel therapeutic approaches in disease resistant to EGFR pathway targeting and accelerate predictive biomarker development...
  55. pmc Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?
    Timothy A Yap
    Drug Development Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    EPMA J 3:3. 2012
    ....
  56. ncbi The evolution of the unstable cancer genome
    REBECCA A BURRELL
    Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3LY, UK
    Curr Opin Genet Dev 24:61-7. 2014
    ....
  57. pmc Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity
    Rosalie Fisher
    Cancer Research UK London Research Institute, Translational Cancer Therapeutics Laboratory, 44 Lincoln s Inn Fields, London WC2A 3LY, UK
    EPMA J 3:1. 2011
    ....
  58. doi A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers
    Rachael Natrajan
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK
    J Pathol 227:29-41. 2012
    ....
  59. ncbi Cell-cycle targeted therapies
    Charles Swanton
    Royal Marsden Hospital Breast Unit, Royal Marsden Hospital NHS Trust, London, UK
    Lancet Oncol 5:27-36. 2004
    ..This review will introduce the protein families that regulate the cell cycle, their aberrations in malignant progression and pharmacological strategies targeting this important process...
  60. ncbi Epothilones and new analogues of the microtubule modulators in taxane-resistant disease
    Michelle Harrison
    Royal Prince Alfred Hospital, Department of Medical Oncology, Missenden Road, Camperdown, Sydney 2050, Australia
    Expert Opin Investig Drugs 17:523-46. 2008
    ..Microtubule-stabilising agents typified by the epothilone class of drug have demonstrated promising activity in Phase II and III clinical trials...
  61. pmc The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel
    Ahmed Ashour Ahmed
    Functional Genomics of Drug Resistance Laboratory, Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK
    Cancer Cell 12:514-27. 2007
    ..These data show that ECM can mediate taxane sensitivity by modulating microtubule stability...